Supplemented by a meta-analysis of the data available at the Oncomine database [159] in favor of higher expression of Spry2 in colon tumors compared with other neoplasias, their results suggested a tumorigenic action and a potential role as a tumor marker for Spry2 in colon cancer. Here, SPRY2 is linked to neoplasm.